• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cell-cell interaction in graft rejection responses: induction of anti-allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen.移植排斥反应中的细胞间相互作用:针对共表达于耐受原上的同种异体II类H-2抗原的免疫反应可阻止抗同种异体I类H-2耐受性的诱导。
J Exp Med. 1992 Jan 1;175(1):99-109. doi: 10.1084/jem.175.1.99.
2
Induction of anti-allo-class I H-2 tolerance by inactivation of CD8+ helper T cells, and reversal of tolerance through introduction of third-party helper T cells.通过使CD8 +辅助性T细胞失活诱导抗同种异体I类H-2耐受性,并通过引入第三方辅助性T细胞逆转耐受性。
J Exp Med. 1990 Jul 1;172(1):105-13. doi: 10.1084/jem.172.1.105.
3
Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.同种异体II类H-2抗原反应性L3T4+辅助性T细胞的耐受性诱导及相应II类H-2不相合皮肤移植物的长期存活。
J Immunol. 1989 Sep 1;143(5):1447-52.
4
Tolerance induction of allo-class I H-2 antigen-reactive Lyt-2+ helper T cells and prolonged survival of the corresponding class I H-2-disparate skin graft.同种I类H-2抗原反应性Lyt-2+辅助性T细胞的耐受性诱导及相应I类H-2不相合皮肤移植物的长期存活。
J Immunol. 1989 Jul 1;143(1):1-8.
5
Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.肿瘤同种异体移植排斥主要由受I类同种异体抗原刺激的CD8 + 细胞毒性T淋巴细胞介导,并与识别II类同种异体抗原的CD4 + 辅助性T细胞协同作用。
J Immunol. 1990 Mar 15;144(6):2425-35.
6
Property of class I H-2 alloantigen-reactive Lyt-2+ helper T cell subset. Abrogation of its proliferative and IL-2-producing capacities by intravenous injection of class I H-2-disparate allogeneic cells.I类H-2同种异体抗原反应性Lyt-2+辅助性T细胞亚群的特性。通过静脉注射I类H-2不同的同种异体细胞消除其增殖和产生白细胞介素-2的能力。
J Immunol. 1988 Aug 1;141(3):721-7.
7
Requirement of the thymus for the recovery of anti-alloantigen helper T cells from tolerance induced by intravenous presensitization with allogeneic cells.胸腺对于从经同种异体细胞静脉预致敏诱导的耐受中恢复抗同种异体抗原辅助性T细胞的必要性。
J Immunol. 1990 Jun 1;144(11):4139-46.
8
Heterogeneity of CD4+ T cells involved in anti-allo-class I H-2 immune responses. Functional discrimination between the major proliferating cells and helper cells assisting cytotoxic T cell responses.参与抗同种异体I类H-2免疫反应的CD4+ T细胞的异质性。主要增殖细胞与辅助细胞毒性T细胞反应的辅助细胞之间的功能区分。
J Immunol. 1991 Apr 15;146(8):2513-21.
9
Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A.急性和慢性移植物抗宿主病中的同种抑制性和同种辅助性T细胞。II. 在H-2K和/或I-A携带突变的F1受体。
J Exp Med. 1983 Feb 1;157(2):755-71. doi: 10.1084/jem.157.2.755.
10
The lymphoid cell populations required for induction of tolerance of different subsets of alloantigen-reactive T cells.
Transplantation. 1991 Nov;52(5):862-7. doi: 10.1097/00007890-199111000-00021.

本文引用的文献

1
Prolonged graft survival by donor-specific blood transfusion (DSBT).通过供体特异性输血(DSBT)延长移植物存活时间。
Transplant Proc. 1982 Jun;14(2):367-9.
2
Update of the University of California at San Francisco experience with donor-specific blood transfusions.加利福尼亚大学旧金山分校关于供体特异性输血经验的最新情况。
Transplant Proc. 1982 Jun;14(2):363-6.
3
The effect of cyclosporin A and blood transfusions on cardiac allograft survival in rats.环孢素A和输血对大鼠心脏同种异体移植存活的影响。
Surgery. 1982 Mar;91(3):339-42.
4
Effect of a single transfusion of donor-specific and nonspecific blood on skin allograft survival in mice.单次输注供体特异性和非特异性血液对小鼠皮肤同种异体移植存活的影响。
Transplantation. 1980 Dec;30(6):421-4. doi: 10.1097/00007890-198012000-00007.
5
The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.扩增性T淋巴细胞增强体外和体内肿瘤特异性T细胞介导的免疫反应。
J Immunol. 1980 Feb;124(2):863-9.
6
Serologic considerations in donor-specific transfusion therapy for kidney transplantation.肾移植供体特异性输血治疗中的血清学考量
Transplant Proc. 1982 Jun;14(2):374-7.
7
Effect of pretransplant donor-specific transfusions in renal transplantation.
Transplant Proc. 1982 Jun;14(2):370-3.
8
A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.一种大鼠抗小鼠T4单克隆抗体(H129.19)可抑制Ia反应性T细胞克隆的增殖,并在抗Ia细胞毒性T细胞克隆中区分出两个表型不同的亚群(T4+、Lyt-2,3-和T4-、Lyt-2,3+)。
J Immunol. 1984 Jun;132(6):2775-82.
9
T cell-accessory cell interactions that initiate allospecific cytotoxic T lymphocyte responses: existence of both Ia-restricted and Ia-unrestricted cellular interaction pathways.引发同种特异性细胞毒性T淋巴细胞反应的T细胞-辅助细胞相互作用:Ia限制型和Ia非限制型细胞相互作用途径的存在。
J Immunol. 1984 May;132(5):2199-209.
10
Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation.抗原反应性T细胞克隆。I. 转互补杂交I-A区基因产物在抗原呈递中有效发挥作用。
J Exp Med. 1980 Oct 1;152(4):759-70. doi: 10.1084/jem.152.4.759.

移植排斥反应中的细胞间相互作用:针对共表达于耐受原上的同种异体II类H-2抗原的免疫反应可阻止抗同种异体I类H-2耐受性的诱导。

Cell-cell interaction in graft rejection responses: induction of anti-allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen.

作者信息

Hori S, Kitagawa S, Iwata H, Ochiai T, Isono K, Hamaoka T, Fujiwara H

机构信息

Biomedical Research Center, Osaka University Medical School, Japan.

出版信息

J Exp Med. 1992 Jan 1;175(1):99-109. doi: 10.1084/jem.175.1.99.

DOI:10.1084/jem.175.1.99
PMID:1730930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2119068/
Abstract

The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-2bm1 (bm1) spleen cells results in almost complete abrogation of anti-bm1 CD8+ helper (proliferative and interleukin 2-producing) T cell (Th) activities. Although an appreciable portion of CD8+ cytotoxic T lymphocyte (CTL) precursors themselves remained after this regimen, such a residual CTL activity was eliminated after the engrafting of bm1 grafts, and these grafts exhibited prolonged survival. In contrast, the intravenous sensitization with (bm1 x B6-C-H-2bm12 [bm12])F1 cells instead of bm1 cells failed to induce the prolongation of bm1 graft survival as well as bm12 and (bm1 x bm12)F1 graft survival. In the (bm1 x bm12)F1-presensitized B6 mice before as well as after the engrafting of bm1 grafts, anti-bm1 CTL responses that were comparable to or slightly stronger than those observed in unpresensitized mice were induced in the absence of anti-bm1 Th activities. bm1 graft survival was also prolonged by intravenous presensitization with a mixture of bm1 and bm12 cells but not with a mixture of bm1 and (bm1 x bm12)F1 cells. The capacity of CD4+ T cells to reject bm12 grafts was eliminated by intravenous presensitization with antigen-presenting cell (APC)-depleted bm12 spleen cells. However, intravenous presensitization with APC-depleted (bm1 x bm12)F1 cells failed to induce the prolongation of bm1 graft survival under conditions in which appreciably prolonged bm12 graft survival was induced. More surprisingly, bm1 graft survival was not prolonged even when the (bm1 x bm12)F1 cell presensitization was performed in CD4+ T cell-depleted B6 mice. This contrasted with the fact that conventional class I-disparate grafts capable of activating self Ia-restricted CD4+ as well as allo-class I-reactive CD8+ Th exhibited prolonged survival in CD4+ T cell-depleted, class I-disparate cell-presensitized mice. These results indicate that: (a) intravenous presensitization with class I- and II-disparate cells fails to reduce anti-allo-class I rejection responses that would otherwise be eliminated using only class I-disparate cells; (b) such failure is generated according to the coexpression of both classes of alloantigens on a single cell as tolerogen; and (c) allo-class II antigens coexpressed on tolerogen function to activate CD4+ as well as non-CD4+ Th leading to the generation of anti-class I effector T cell responses.

摘要

用I类H - 2不同的B6 - C - H - 2bm1(bm1)脾细胞对C57BL / 6(B6)小鼠进行静脉致敏,几乎可完全消除抗bm1 CD8 +辅助(增殖性和产生白细胞介素2的)T细胞(Th)活性。尽管在此方案后仍有相当一部分CD8 +细胞毒性T淋巴细胞(CTL)前体自身保留,但在植入bm1移植物后,这种残留的CTL活性被消除,并且这些移植物存活时间延长。相比之下,用(bm1×B6 - C - H - 2bm12 [bm12])F1细胞而非bm1细胞进行静脉致敏,未能诱导bm1移植物存活时间延长,也未能诱导bm12和(bm1×bm12)F1移植物存活时间延长。在植入bm1移植物之前和之后,在(bm1×bm12)F1预致敏的B6小鼠中,在没有抗bm1 Th活性的情况下,诱导出了与未预致敏小鼠中观察到的相当或略强的抗bm1 CTL反应。用bm1和bm12细胞的混合物进行静脉预致敏也可延长bm1移植物存活时间,但用bm1和(bm1×bm12)F1细胞的混合物则不能。用去除抗原呈递细胞(APC)的bm12脾细胞进行静脉预致敏可消除CD4 + T细胞排斥bm12移植物的能力。然而,在可诱导bm12移植物明显延长存活时间的条件下,用去除APC的(bm1×bm12)F1细胞进行静脉预致敏未能诱导bm1移植物存活时间延长。更令人惊讶的是,即使在CD4 + T细胞缺失的B6小鼠中进行(bm1×bm12)F1细胞预致敏,bm1移植物存活时间也未延长。这与以下事实形成对比:能够激活自身Ia限制的CD4 +以及同种I类反应性CD8 + Th的传统I类不同移植物,在CD4 + T细胞缺失、I类不同细胞预致敏的小鼠中存活时间延长。这些结果表明:(a)用I类和II类不同细胞进行静脉预致敏不能降低抗同种I类排斥反应,而仅用I类不同细胞进行预致敏则可消除该反应;(b)这种失败是由于两类同种抗原在单个细胞上作为耐受原共同表达所致;(c)在耐受原上共同表达的同种II类抗原起到激活CD4 +以及非CD4 + Th的作用,从而导致产生抗I类效应T细胞反应。